Starboard's Kenvue complaints are much different than those aimed at Pfizer

Max Bayer

Pharma Reporter

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — Johnson & Johnson’s consumer spinout Kenvue.

In a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Starboard's Kenvue complaints are much different than those aimed at Pfizer

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Be Bio raises $82M to fund work on B cell therapy in hemophilia B

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Star­board­'s Ken­vue com­plaints are much dif­fer­ent than those aimed at Pfiz­er

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Starboard's Kenvue complaints are much different than those aimed at Pfizer